Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
News|Articles|March 18, 2013
Waters Corp. Updates Instruments and Software
Author(s)Pharmaceutical Technology Editors
At Pittcon 2013, Water Corp. announced improvement to chromatography systems and software.
At Pittcon 2013 in Philadelphia,
The company reported enhancements to the Waters Alliance HPLC system that will maintain key Alliance performance specifications and control algorithms to ensure that analysts can replicate their existing methods. The system features updated electronics and user interface. The updated systems can be used with Waters eXtended Performance [XP], 2.5 μm columns.
The company also announced an expansion of its laboratory informatics offerings, with the addition of Paradigm Scientific Search Software, which allows users to perform object-based searches across both structured and unstructured data and across different data platforms.
Mobile access and new laboratory analytics enhancements were added to Empower 3 chromatography data software.
Quality Control Reference Materials (QCRMs) and Certified Containers for Waters instruments were added to the Analytical Standards and Reagents product group.
Another technology introduction is the Waters ACQUITY Advanced Polymer Chromatography (APC) System, the company says, defines a new category of chromatographic polymer analysis, yielding improved molecular weight information about polymeric species, faster than ever before.
Waters Corp. announced updates to the Alliance HPLC system and Empower 3 chromatography data software, and introduced search software and reference materials.
Related to this article
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.